

# A prospective, randomised, double-blinded study to compare bipolar transurethral resection of the prostate (bipolar TURP) versus monopolar transurethral resection of the prostate (monopolar TURP) in terms of safety and efficacy

<b>Submission date</b>	<b>Recruitment status</b>	<input type="checkbox"/> Prospectively registered
21/07/2006	No longer recruiting	<input type="checkbox"/> Protocol
<b>Registration date</b>	<b>Overall study status</b>	<input type="checkbox"/> Statistical analysis plan
21/07/2006	Completed	<input type="checkbox"/> Results
<b>Last Edited</b>	<b>Condition category</b>	<input type="checkbox"/> Individual participant data
19/09/2007	Urological and Genital Diseases	<input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Dr S.A. Lagerveld-Zaaijer

### Contact details

Academic Medical Center (AMC)

Department of Urology

P.O. Box 22660

Amsterdam

Netherlands

1100 DD

+31 (0)20 5666030

S.A.Zaaijer@amc.uva.nl

## Additional identifiers

### Protocol serial number

N/A

## Study information

### Scientific Title

### Acronym

TURP

### Study objectives

Bipolar devices will minimise the disadvantages of the monopolar device such as the risk of electrolyte disturbances by using saline irrigation, bleeding and the risk of nervous stimulation.

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

Not provided at time of registration.

### Study design

A prospective, randomised, double-blinded study

### Primary study design

Interventional

### Study type(s)

Treatment

### Health condition(s) or problem(s) studied

Benign Prostatic Hyperplasia (BPH)

### Interventions

Patients will be randomised into either:

Group A: who will undergo a bipolar TURP

Group B: who will undergo a monopolar TURP

### Intervention Type

Other

### Phase

Not Specified

### Primary outcome(s)

1. Safety bipolar TURP compared with monopolar TURP by means of transurethral resection (TUR) syndrome
2. Blood loss
3. Number and severity of adverse events

### Key secondary outcome(s))

1. Efficacy of bipolar TURP compared with monopolar TURP by means of IPSS or quality of life (QoL) scores
2. International index of erectile function (IIEF) score
3. Qmax
4. Cutting rate
5. Length of catheterisation
6. Length of hospital stay
7. Length of operation
8. Impact on prostate specific antigen (PSA) level
9. Number of strictures

**Completion date**

31/12/2010

## Eligibility

**Key inclusion criteria**

1. Candidates for transurethral resection of the prostate (TURP)
2. Qmax less than 16 ml/sec
3. International Prostate Symptom Score (IPSS) score greater than 14
4. Voided volume greater than 125
5. Patients in retention with an indwelling catheter or intermittent catheterisation
6. Informed consent

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Sex**

All

**Key exclusion criteria**

1. If patient is suspected to be suffering from prostate cancer
2. Prior prostate surgery, including minimal invasive therapies
3. Active urinary tract infection
4. Known or suspected neurogenic decompensated bladder (postvoid residual urine volume [PVR] greater than 400ml/sec) or compensated detrusor function
5. Immunosuppression; using prednisone
6. Known or suspected malignant disease affecting the bladder or lower urinary tract
7. 5-alpha-reductase inhibitor within the last three months before baseline
8. Alpha-blockers within the last six weeks before baseline
9. Specific severe heart disease in whom anti-coagulant therapy might jeopardize treatment outcome

**Date of first enrolment**

01/07/2006

**Date of final enrolment**  
31/12/2010

## Locations

**Countries of recruitment**  
Netherlands

**Study participating centre**  
Academic Medical Center (AMC)  
Amsterdam  
Netherlands  
1100 DD

## Sponsor information

**Organisation**  
Academic Medical Center (AMC), Department of Urology (The Netherlands)

**ROR**  
<https://ror.org/03t4gr691>

## Funder(s)

**Funder type**  
Industry

**Funder Name**  
Karl Storz (UK)

**Funder Name**  
Academic Medical Center (AMC) (The Netherlands) - Department of Urology

## Results and Publications

**Individual participant data (IPD) sharing plan**

## IPD sharing plan summary

Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Study website</a>	Study website	11/11/2025	11/11/2025	No	Yes